Skip to main content
. 2022 Jul 28;23(15):8333. doi: 10.3390/ijms23158333

Table 6.

Patients’ characteristics.

Patient No. Age, Sex Stage FAB Type Blast Phenotype (CD) IC Blasts (%) Source Conducted Experiments
AML
1172 24, m dgn p-M0 117,13,33,34 92 MNC, WB DCC
993 71, m dgn p-M1 34,13,33,117 95 MNC, WB DCC
1289 65, w dgn p-M1 34,33, 56,117 60 WB DCC
1300 24, w dgn p-M1 34,13,33,65,117 75 WB DCC, CTX
1190 72, m dgn p-M2 117,33,34 28 MNC, WB DCC
1292 44, w dgn p-M2 117,13,33,34 78 WB DCC, CTX
1295 40, m dgn p-M2 34,13,33,117 45 WB DCC
1225 48, m dgn p-M3 117,13,33 77 MNC, WB DCC
1327 61, m dgn p-M4 117,7,13,33,65 75 WB DCC
1453 54, w dgn p-M4 15,14,33,64,56 52 WB DCC, CTX
1459 54, m dgn p-M4 56,4,11c,11b,33,38,64 14 WB DCC, CTX
1460 78, w dgn p-M4 15,34,117 68 WB DCC, CTX
1430 79, m dgn p-M5 34,117,13,33 70 WB DCC, CTX
1432 34, m dgn p-M5 34,13,33,64 81 WB DCC, CTX
1447 21, m dgn p-M5 33,56,45 65 WB DCC, CTX
1443 64, m dgn p-M? 34,117,13,33 50 WB DCC
1452 44, m dgn p-M? 34,117,33,13,45 55 WB DCC, CTX
1050 32, w dgn s-M1 117,14,13,33 90 MNC, WB DCC
1144 32, m dgn s-M1 34,13,19,56,117 60 MNC, WB DCC
1204 72, m dgn s-M2 117,13,56 43 MNC, WB DCC
1131 53, w dgn s-M4 117,33 15 WB DCC
1207 56, w dgn s-M4 117,4,13,15,33,34 10 MNC, WB DCC
1442 73, w dgn s-M4 117,33,61,138 14 WB DCC, CTX
1426 61, w dgn s-M5 34,117,13,33,64 93 WB DCC, CTX
1439 61, w dgn s-M5 34,117,13,33 17 WB DCC
999 51, w dgn s-M? 34,13,33,65,117 14 MNC, WB DCC
1056 27, m dgn s-M? 117,13,15,33,34 42 MNC, WB DCC
1165 59, m dgn s-M? 34,13,33,117 46 MNC, WB DCC
1194 72, m dgn s-M? 34,33,117 18 MNC, WB DCC
1196 39, w dgn s-M? 117,33 11 MNC, WB DCC
1226 69, m dgn s-M? 117,33,34 65 MNC, WB DCC
1385 82, m dgn s-M? 34,13,56,117 23 WB DCC, CTX
1434 61, w dgn s-M? 34,117,7,13,33,56,64 61 WB DCC, CTX
1449 78, m dgn s-M? 15,65,4,45,64 62 WB DCC, CTX
1454 60, w dgn s-M? 34,117,20,61 33 WB DCC
1024 39, m pers p-M2 34,33,117 88 MNC, WB DCC
1218 54, m pers p-M2 33,56,13 30 MNC, WB DCC
1201 60, w pers p-M5b 34,4,13,14,15,33,56,6,5 63 WB DCC
1320 66, m pers s-M6 34,65,117 15 WB DCC, CTX
1310 77, w pers s-M? 117,33,34,56 52 WB DCC
1011 88, w rel p-M1 34,13,33,65,117 88 MNC, WB DCC
1127 61, w rel p-M1 34,13,33,117 46 MNC, WB DCC
1138 24, m rel p-M1 34,4,14,33,56,65,117 50 MNC, WB DCC
1222 40, m rel p-M1 117,33,34,56 50 MNC, WB DCC
1080 37, w rel p-M2 34,4,13,33,117 34 MNC, WB DCC
1123 70, m rel p-M2 34,13,33,117 47 MNC, WB DCC
1205 60, m rel p-M2 34,2,13,33,117 67 MNC, WB DCC
1206 74, w rel p-M2 34,4,33,117 27 MNC, WB DCC
1243 34, m rel p-M2 34,2,13,33,117 32 MNC, WB DCC
1376 52, w rel p-M2 34,33,117 60 WB DCC, CTX
1387 63, m rel p-M2 34,13,33,117 37 WB DCC, CTX
1001 60, w rel p-M4 34,33,117 35 MNC, WB DCC
1017 67, m rel p-M4 34,33,117 34 MNC, WB DCC
1018 40, w rel p-M4 34,15,33,64,117 17 MNC, WB DCC
1143 46, w rel p-M4 117,2,7,13,34,65 75 MNC, WB DCC
998 67, m rel p-M5a 34,4,64,117 92 MNC, WB DCC
1263 40, m rel p-M5 34,19,33,117 18 WB DCC
1375 44, w rel p-M5 34,15,33,117 35 WB DCC, CTX
1303 64, w rel s-M4 34,4,13,33,14,56,65 65 WB DCC, CTX
1286 21, m rel s-M5 117,33,34 35 WB DCC, CTX
987 61, m rel s-M? 34,13,33,117 21 MNC, WB DCC
1183 36, w rel s-M? 34,33,117 33 MNC, WB DCC
1307 54, m rel s-M? 117,13,15,19,33,34,65 30 WB DCC, CTX
1386 57, m rel s-M? 34,33,117 78 WB DCC, CTX
MDS
1433 59, m 34,117,14,33 14 WB DCC, CTX
1306 42, m 117,13,33,34 11 WB DCC, CTX

AML acute myeloid leukaemia; MDS myelodysplastic syndrome; m male; f female; pAML primary AML; sAML secondary AML; FAB french-american-british classification; M? FAB type not classified; dgn diagnosis; pers persistance; rel relapse; IC blasts immunocytologically determined blasts; WB whole blood; MNC mononuclear cells; DCC dendritic cell culture; CTX cytotoxicity fluorolysis assay; bold markers were used to detect DCleu.